rs2295080 — MTOR

MTOR rs2295080 — The Longevity Pathway's Genetic Dimmer Switch

mTOR (mechanistic target of rapamycin) is arguably the most powerful longevity-relevant kinase in human biology. It integrates signals from nutrients, amino acids, growth factors, and energy status to control cell growth, protein synthesis, and — critically — autophagy¹¹ autophagy
the cellular garbage-disposal process that clears damaged proteins and organelles; inhibition of mTOR is the primary trigger for autophagy induction. When mTOR activity is chronically high, cells prioritize growth and suppress the housekeeping functions that prevent aging; when mTOR is appropriately restrained, autophagy runs, senescent cells are cleared, and lifespan extends across every organism where this has been tested.

The rs2295080 T>G variant sits in the promoter of the MTOR gene on chromosome 1 and acts as a functional dimmer switch for mTOR expression. Individuals carrying the G allele have measurably lower MTOR mRNA levels in their tissues, confirmed by luciferase reporter assays showing the G allele significantly decreases promoter transcriptional activity. The G allele essentially dials mTOR expression down²² The G allele essentially dials mTOR expression down
Cao Q et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLOS One, 2012.

The Mechanism

rs2295080 is located approximately 2 kb upstream of the MTOR coding sequence, placing it in the core promoter region that controls transcription initiation. The T→G change alters a transcription factor binding site, reducing the efficiency with which the transcriptional machinery assembles and initiates MTOR mRNA production. The result is a genotype-dependent gradient of mTOR activity: TT > GT > GG.

Lower constitutive mTOR expression has several downstream effects. mTORC1 (the nutrient-sensing complex) phosphorylates S6 kinase and 4E-BP1 to drive protein synthesis; when this activity is reduced, cells shift resources toward protein quality control and autophagy induction. mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested³³ mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested
Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging, 2023. Genetic lower expression via rs2295080 may mimic, in a modest and constitutive way, the longevity biology of intermittent mTOR suppression.

The Evidence

The primary evidence base for rs2295080 consists of cancer risk studies, which are the clearest functional readout of mTOR overactivity: elevated mTOR drives cell proliferation and suppresses apoptosis, so genotypes with higher mTOR expression should show elevated cancer susceptibility.

Gastric cancer (n=1,607)⁴⁴ Gastric cancer (n=1,607)
Xu M et al. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLOS One, 2013: the G allele was associated with a 23% lower risk of gastric cancer (OR 0.77, 95% CI 0.65–0.92, P=0.004).

Colorectal cancer (n=1,514)⁵⁵ Colorectal cancer (n=1,514)
Xu M et al. Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population. Biomed Pharmacother, 2015: carriers of TG or GG genotypes had a 24% lower risk of colorectal cancer (OR 0.76, 95% CI 0.62–0.94, P=0.011); the effect was stronger in men and the elderly (OR 0.63 and 0.66, respectively).

Renal cell cancer (n=1,470)⁶⁶ Renal cell cancer (n=1,470)
Cao Q et al. 2012: the G allele was associated with reduced RCC risk (OR 0.74, 95% CI 0.59–0.91, P=0.005).

Breast cancer (n=1,143)⁷⁷ Breast cancer (n=1,143)
Zhao Y et al. 2016: GG homozygotes had a 55% lower breast cancer risk (OR 0.45, 95% CI 0.23–0.91, P=0.02) and lower rates of lymph node metastasis.

A comprehensive meta-analysis of 18 Chinese studies⁸⁸ A comprehensive meta-analysis of 18 Chinese studies
Qi GH et al. 2020 confirmed decreased risk for urinary system tumors and prostate cancer (heterozygote OR 0.80, P<0.001), while noting a paradoxical increased leukemia risk in GG homozygotes — a finding that requires further study and likely reflects cancer-type-specific mTOR biology.

Most studies have been conducted in Chinese populations; replication in European and other populations is warranted, which is reflected in the moderate evidence rating.

Practical Actions

The actionable implications of rs2295080 center on how your genotype shapes the ideal strategy for managing mTOR activity over time. Regardless of genotype, mTOR is suppressed by fasting, protein restriction, and exercise, and activated by dietary protein (especially leucine/BCAAs), insulin, and growth factors. But the baseline level of MTOR expression differs by genotype, which affects how aggressively these lifestyle tools need to be applied.

TT carriers have higher constitutive mTOR activity — they benefit most from deliberate mTOR-suppression protocols: extended overnight fasting (14–16 hours), periodic protein cycling (low protein days), and close attention to protein timing relative to meals. GT carriers have an intermediate baseline and similar considerations at lower urgency. GG carriers enjoy naturally lower mTOR expression, meaning their cells engage autophagy more readily, but they may also need to ensure adequate protein intake to support muscle protein synthesis since mTOR plays a key anabolic role.

Interactions

rs2295080 is part of the broader PI3K-AKT-mTOR signaling axis. Related SNPs worth considering include rs2536 (another mTOR variant studied for cancer risk), and upstream regulators like variants in PTEN (which normally suppresses AKT/mTOR activity) and AMPK pathway genes. FOXO3A (rs2802292) operates in the same longevity signaling network: FOXO3 is normally phosphorylated and inactivated by AKT downstream of mTOR, so G-allele carriers at both rs2295080 (lower mTOR) and rs2802292 (higher stress-induced FOXO3 expression) would be expected to have complementary longevity biology through this pathway. This interaction is biologically plausible but has not been formally tested in a combined genotype study.